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Introduction

Cardiovascular disease is a significant cause of morbidity
and the leading cause of mortality in both the United States
and worldwide.1,2 Given the considerable burden of disease,
cardiac risk assessment is an especially important element
of preoperative evaluation prior to noncardiac general
surgery.3 Globally, an estimated 100 million adults undergo
noncardiac surgery each year,4 more than one third of whom
have underlying coronary artery disease (CAD). 5 Cardiac
complications, including cardiac death, nonfatal myocardial
infarction (MI), and nonfatal cardiac arrest, represent major
causes of peri- and postoperative morbidity and mortality. 6
The incidence of such cardiac complications is an estimated
1.4% in relatively unselected patients,7 with an even greater
incidence (2.4 – 5.8%) among those with or at risk of cardiac
disease. 8,9,10,11,12,13 Annually, more than one million patients
are likely to experience such a complication.6 The magnitude
of this problem can be measured not only in patient health
outcomes and illness burden, but also in terms of the large cost
subsequently imposed upon the healthcare system, especially as
the number of noncardiac surgical patients at risk for adverse
cardiac outcomes continues to increase.14
A common underlying pathophysiology posited to mediate
perioperative myocardial infarctions is atherosclerotic plaque
disruption, which leads to coronary vessel obstruction,15 as well
as prolonged ischemia.16 Perioperative myocardial ischemia is a
consequence of an exaggerated sympathetic response, evidenced
by increased myocardial oxygen demand and decreased
coronary diastolic filling time (secondary to increases in heart
rate and contractility caused by physiologic stress and elevated
catecholamine levels).17
The exact mechanism by which beta-blockers reduce
perioperative cardiac complications remains unclear. It has been
proposed that through attenuation of the sympathetic response,
with the major effects of reduction in heart rate (leading to
increased perfusion time) and contractility (leading to decreased
oxygen demand), perioperative beta-blockade results in a
reduction in both cardiac caused mortality and the incidence
of cardiovascular complications.18 Another hypothesis is that
it is optimal heart rate control, rather than a specific agent,
that is associated with a decline in ischemic events, as cardiac
damage often results from inadequate myocardial blood flow.16
Additional potential cardiovascular effects of perioperative beta
blockade include “vulnerable” coronary plaque stabilization and
dysrhythmia prophylaxis.19

Perioperative Beta-Blockade: Evolution of the Evidence

Initial randomized trials, including the landmark study on which
the original 1996 American College of Cardiology/American
Heart Association (ACC/AHA) recommendations20 were based,

suggested that beta-blockers reduce perioperative ischemia in
patients with underlying arterial disease. 18 Mangano et al 18
performed a randomized, double-blind, placebo-controlled
study comparing the effects of atenolol with those of a placebo
on overall survival and cardiovascular morbidity in individuals
undergoing noncardiac surgery with coronary artery disease
(history of MI, typical angina, or atypical angina with positive
stress test result) or risk factors for coronary artery disease (≥2
of the following: age >65 years, hypertension, current smoker,
cholesterol level >240 mg/dL, or diabetes). Results of this
study of 200 patients demonstrated that, in this population,
perioperative atenolol (administered intravenously 30 minutes
prior to surgery and continued by mouth throughout the hospital
stay for up to 7 days) significantly reduced overall mortality
and incidence of cardiovascular complications for as long as
two years following discharge, with the primary effect identified
as a decrease in mortality from cardiac causes during the first
six to eight months. Atenolol administration, however, did not
significantly reduce cardiac causes of mortality during hospitalization or incidence of perioperative MI. This lack of effect of
atenolol in the perioperative period, however, may have been a
result of the low incidence of significant perioperative cardiac
events among study population patients, thus demonstrating a
potential limitation of the study.
Subsequent research continued to contribute to a mounting body
of evidence supporting perioperative beta-blockade in patients
undergoing noncardiac surgery at high risk for adverse cardiac
outcomes. In 1999, the Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography (DECREASE)
Study Group21 reported a randomized, non-blinded, placebocontrolled, multi-center trial examining the effect of bisoprolol
on perioperative mortality and myocardial infarction in a
subgroup of high-risk patients undergoing vascular surgery.
High-risk patients were identified by the presence of both
clinical risk factors and dobutamine stress echocardiography
results positive for ischemia. Subjects were randomized and
treatment group patients received standard perioperative care
plus bisoprolol (initial dose at least one week prior to surgery
and continued for thirty days postoperatively, with subsequent
dosing individually adjusted by physician based on heart rate).
Study endpoints were defined as cardiac death and myocardial
infarction. A majority of the adverse cardiac events in both
groups occurred during the first seven days following surgery.
Overall study findings indicated a reduction in perioperative
incidence of cardiac causes of mortality and nonfatal MI with
the perioperative administration of bisoprolol. Despite the
lack of significant clinical and echocardiogram differences
between the standard care and treatment groups, the combined
incidence of cardiac events in the standard care group was
34%, compared to 3.4% in the bisoprolol group. This striking
difference demonstrated a substantial benefit to treatment,
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significant enough to cause the investigation safety committee
to suspend the study.
Based on investigation results, the DECREASE Study Group
recommended that high-risk surgical patients receive
beta-blockers perioperatively, with initiation one to two weeks
preoperatively and continuation for at least two weeks postoperatively, with a goal of heart rate reduction to <70 beats/
minute preoperatively and <80 beats/minute in the immediate
postoperative period. Investigators also suggested a potential
alternative approach to standard preoperative management,
proposing exclusion of preoperative non-invasive cardiac
testing and replacement with prescription of perioperative
beta-blockade for all patients with clinical risk factors undergoing
high-risk surgery. Major limitations of this study were the fact
that it was not blinded, thus allowing for potential bias and
reporting error, and its focus only on a specific subpopulation.21
Prevention of perioperative morbidity and mortality is not the
only consideration in the initial preoperative evaluation of a
patient. Also important is the assurance of long-term future
survival. As such, a related, follow-up study by the DECREASE
Study Group22 assessed the long-term cardioprotective effects
of perioperative and prolonged postoperative beta-adrenergic
blockade with bisoprolol in the same, randomized cohort
of high-risk patients following successful major noncardiac
vascular surgery. Again, study treatment dosage was adjusted by
physicians based on prescribed heart rate guidelines. Two-year
follow-up was complete in all patients, monitoring for the
occurrence of late cardiac events, including cardiac death and
myocardial infarction. With no significant differences in clinical
characteristic between the treatment and control groups,
combined perioperative and long-term postoperative bisoprolol
administration resulted in a significant, three-fold decrease in
the incidence of late cardiac death and MI among high-risk
patients after surviving major vascular surgery. However, similar
to the previous study, patients and physicians were not blinded
to the treatment. In addition, pre-trial risk of cardiac events
in the two study groups may not have been comparable; the
standard treatment group included survivors of perioperative
MI, who may have consequently been at increased risk of late
cardiac events during follow-up, and elevated incidence of
perioperative mortality in the standard treatment group may
also have eliminated the highest risk patients in this group.
Further trials evaluating the use of perioperative beta-blockers
in patients undergoing noncardiac surgery did not produce
favorable results, which challenges their efficacy and safety.
Randomized controlled trials, including the Diabetic
Postoperative Mortality and Morbidity (DIPOM) trial23 and the
Metoprolol after Vascular Surgery (MaVS) study,24 demonstrated
a lack of benefit of perioperative beta-blockade among specific
patient populations, though there were limitations in the
designs of these trials. More notably, the recent POISE trial,25
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a large, multinational, multicenter, randomized, double-blind,
placebo-controlled trial, was conducted to investigate the effects
of perioperative beta-blockers in patients with risks for atherosclerosis or known atherosclerosis undergoing noncardiac
surgery. Patients were randomized to receive either placebo
or extended-release metoprolol succinate, which was initiated
two to four hours prior to surgery and continued for 30 days
postoperatively. Intention to treat analysis was conducted on
a population of 8351 patients, and the primary endpoint was
a composite of cardiovascular death, non-fatal myocardial
infarction, and non-fatal cardiac arrest. At follow-up 30 days
postoperatively, while significantly fewer treatment group
patients reached the primary endpoint (an outcome driven
entirely by a significant reduction in MI among treated patients),
the incidences of both death and stroke were significantly
greater in the metoprolol group. Though other factors may be
responsible, investigators associated these findings primarily to
the clinically significant hypotension and bradycardia associated
with beta-blockade. Subsequent meta-analyses of trials of
perioperative beta-blockers including POISE revealed some
similarities in results and consistency with POISE findings.
Meta-analyses demonstrated a risk reduction in non-fatal MI
with beta-blockade, but also suggested an increased risk of death
and non-fatal stroke with use of perioperative beta-blockers.
The POISE study represents the largest trial conducted to date
addressing perioperative beta-blockers in patients undergoing
noncardiac surgery. It is important to recognize, however,
that this study too has its limitations. This trial utilized a very
high and fixed dose of metoprolol (initial dose 2-8 times the
commonly prescribed dose with no adjustment for heart
rate). Additionally, therapy was initiated shortly (only hours)
before surgery. Also of note is that in all of the meta-analyses
conducted, POISE data accounted for approximately 80% of
the patients. Results do, however, underscore the potential risks
underlying the assumption that perioperative beta-blockade is
beneficial and without harm.

Evidence Limitations

The role of beta-blockers in the perioperative setting is not
yet clearly defined. Few randomized trials of medical therapy
to prevent major perioperative adverse cardiac events have
been performed, and most trials do not have sufficient power.
Despite evidence from some trials demonstrating the potential
benefit of perioperative beta-blockade in high-risk patients,
much controversy still surrounds their use, especially given the
methodological limitations of prior studies. No single agent,
dose, route of administration, dosing schedule, or duration of
treatment has been shown to be most effective. In addition, few
studies have examined the effect of titration of therapy (i.e., to
a target heart rate). Other controversial issues include the use
of long- versus short-acting agents, effects of beta-blockade in
patients on chronic beta-blocker therapy prior to surgery versus
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beta-blocker naive patients, and genetic variability in response
to beta-blockade. 26 Future research should aim to identify
the optimal beta-blocking agent as well as define the role of
perioperative beta-blockade in intermediate- and low-risk
populations. To date, no literature has addressed the important
topic of care-delivery mechanisms in the perioperative setting,
identifying how, when, and by whom perioperative beta-blocker
therapy should be implemented and monitored. More evidence
is needed to corroborate the findings of previous studies and
provide future direction. Further study will contribute to
improved understanding, elucidation of these issues, and better
clinical application of the available data.

Current Guidelines

While POISE trial investigators concluded a need for revision of the
approach to the use of perioperative beta-blockers, current ACC/
AHA guidelines,27 published in 2006, which include a focused
update on perioperative beta-blocker therapy, still endorse a
relatively wide indication for perioperative beta-blockade. Class
I recommendations include: 1) continuation of beta-blockers in
patients undergoing surgery who are prescribed beta-blocker
therapy for angina, symptomatic arrhythmias, hypertension, or
other ACC/AHA Class I guideline indications, and 2) administration of beta-blockers to patients undergoing vascular surgery
at high cardiac risk with ischemia on preoperative testing. In
addition, based on Class IIa recommendations, beta-blockers
are probably recommended for 1) patients undergoing vascular
surgery with evidence of coronary heart disease on preoperative
testing, 2) patients in whom preoperative evaluation for
vascular surgery identifies high cardiac risk, and 3) patients in
whom preoperative assessment identifies coronary heart disease
or high cardiac risk and who are undergoing intermediate- to
high-risk procedures. According to Class IIb recommendations,
beta-blockade may also be considered for 1) patients who are
undergoing intermediate- or high-risk procedures in whom a
single clinical cardiac risk factor is identified preoperatively,
and 2) patients undergoing vascular surgery with low cardiac
risk not currently on beta-blockers.
Though an approach to documenting cardiac risk different
from the AHA/ACC guidelines, the Revised Cardiac Risk Index
(RCRI)7 is another extensively tested and accurate estimate of
risk that can be utilized to guide care.28 The RCRI accounts for six
variables: 1) high risk type of surgery, 2) ischemic heart disease,
3) history of congestive heart failure, 4) history of cerebrovascular disease, 5) insulin-dependent diabetes mellitus, and
6) chronic renal insufficiency (preoperative serum creatinine
>2.0 mg/dL). Based on this method of preoperative risk stratification, subsequent risk of major cardiac complications with
noncardiac surgery is estimated as illustrated in Figure 1, with
and without beta-blocker therapy.28

Figure 1.
Risk
Stratification
Low Risk

RCRI
criteria

Risk without
adrenergic
blockade (%)

Risk with
beta-blockade
(%)

0

0.4-1.0

<1

Intermediate
Risk

1-2

2.2-6.6

0.8-1.6

High Risk

≥3

>9

>3

Where Do We Go From Here?

What, then, are the consequences of the results of the POISE trial
for the use of perioperative beta-blockers in clinical practice? In
using the treatment regimen outlined by the DECREASE Study
Group, a low-dose, long-acting agent titrated to effect at least 7
days prior to surgery, a greater overall benefit to perioperative
beta-blockade is seen as compared to risk. The POISE trial,
however, demonstrates that acute administration of high-dose
beta-blocker therapy may be associated with greater risk than
benefit. Given all of the data, we do not believe that the evidence
supports the initiation of prophylactic perioperative beta-blocker
therapy in low- to intermediate risk patients (RCRI £2)
undergoing noncardiac surgery. While beta-blockers do appear
to decrease the risk of perioperative MI, the observed increases
in the rates of stroke and mortality likely outweigh this benefit.
A majority of the myocardial infarctions will be asymptomatic,
but a few will result in serious complications in the perioperative
period. In contrast, most strokes will be seriously disabling or
incapacitating. However, perioperative beta-blockade still likely
has significant cardioprotective effects in high-risk patients
(RCRI ≥3) or patients with evidence of significant ischemia by
preoperative evaluation. In these patients, use of a beta-blocker
perioperatively, with possible continuation in the postoperative
period seems most prudent, with additional consideration for
whether the patient is on chronic beta-blocker therapy prior to
surgery or is beta-blocker naïve. Beta-blockers should be started
orally days, if possible even weeks prior to the scheduled date of
surgery to allow gradual up-titration of the dosage to achieve
optimal heart rate and blood pressure control.

Conclusion

Cardiac complications of noncardiac surgery result in substantial
morbidity and mortality, posing a serious health problem,
whose magnitude only threatens to increase as the incidence of
CAD rises and the population ages. As such, an accurate tool
for cardiac risk assessment as well as sound guidelines for the
subsequent prevention of such adverse outcomes is essential in
moving forward. In select patients, perioperative beta-blockade
may provide a safe and effective method of cardioprotection.
However, it is crucial to highlight that as per the POISE trial,
initiating perioperative beta-blockade is not without its own set
of complications. Therefore, identification of the appropriate
target population, avoidance of the adverse outcomes of
such drugs, and future research aimed at characterizing the

7

Best of Cardiology

appropriate therapeutic regimen are needed in order to achieve
the goal of reduced morbidity and mortality.
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